Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl
-
Sunesis Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
-
Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals Inc. (SNSS) to Spec. Buy
-
Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights
-
Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights
-
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
-
Sunesis to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
-
Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights
-
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights
-
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent Highlights
-
Notable Analyst Rating Changes 12/10: (SNSS) (AAL) (EQT) Upgraded; (S) (MPO) (ALLT) Downgraded
-
Pre-Open Stock Movers 12/10: (SNSS) (RVLT) (COST) Higher; (GDP) (ALLT) (YUM) Lower (more...)
-
UPDATE: Cantor Fitzgerald Upgrades Sunesis Pharmaceuticals (SNSS) to Buy; Analyst Thinks FDA Will Consider NDA
-
Notable Analyst Rating Changes 10/7: (IR) (ADHD) (AAPL) Upgraded; (SNSS) (DE) (CBSH) Downgraded
-
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
-
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
-
Sunesis Pharma (SNSS) Prices $43M Common Stock + Warrants Offering
-
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
-
Sunesis Pharmaceuticals (SNSS) Plans Common, Warrants Offering
-
Sunesis Announces Proposed Public Offering of Common Stock and Warrants
-
Sunesis Pharmaceuticals (SNSS) Tops Q3 EPS by 4c
-
Sunesis Pharmaceuticals (SNSS) Raises Equity Deal with Cantor by $30M
-
Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin
-
Morning Movers 04/13: (PRMW) (JOEZ) (CSTR) Higher; (PWAV) (NEI) (JADE) Lower
-
Cantor Fitzgerald Starts Sunesis Pharmaceuticals (SNSS) at Buy
-
Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals (SNSS) to Hold

